Locations:
Search IconSearch
December 10, 2017/Cancer/Research

Predictors of 30-day Unplanned Readmissions in Patients with Hematologic Malignancies

Disease-related, clinical and discharge-associated factors

mukherjee_650x450

Patients with hematologic malignancies (HM) are at risk of recurrent 30-day unplanned readmissions (UR), given high symptom burdens and repeated courses of chemotherapy. A team of Cleveland Clinic researchers, led by Sudipto Mukherjee, MD, PhD, MPH, recently sought to identify predictors of recurrent 30-day UR in patients with HM as a first step toward designing interventions for this group. Girish Kunapareddy, MD, MBA, a fellow at Cleveland Clinic Cancer Center, was first author on the abstract.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The study included 259 30-day UR involving 157 hematologic malignancy patients treated at Cleveland Clinic between 2012 and 2015. Hematologic malignancies included in the analysis were acute leukemias, myelodysplastic syndromes and aggressive lymphomas. The tables below show disease-related, clinical and discharge-associated factors that are associated with 30-day UR and independently predictive of subsequent 30-day UR.

”We found several predictors of recurrent 30-day UR, notably gastrointestinal symptoms, prior admission for febrile neutropenia, those with relapsed refractory disease and constitutional symptoms, among others,” says Dr. Mukherjee, associate staff in the Department of Hematology and Medical Oncology at Cleveland Clinic Cancer Center. “These data shed light on potential areas that can be targeted for interventions to reduce these UR, which are a significant burden on these patients and not an optimal use of medical resources.” For instance, the subset of patients with relapsed/refractory disease may particularly benefit from a specialized program that includes individualized symptom management from a coordinated team and closer ambulatory follow-ups. As part of efforts to reduce 30-day UR, Cleveland Clinic has instituted five-day follow-up for all cancer patients discharged after hospitalization.

Photo Credit: ©Russell Lee

Advertisement

Related Articles

Male patient with doctor
June 17, 2026/Cancer/Patient Support

Overcoming Taboos: Helping Men with Cancer Restore Sexual Health

Creating a safe space for patients

Masked patient with physician
June 15, 2026/Cancer/Patient Support

Managing Infection Risk in the Era of Cell Therapy

Long-term immune effects reshape preventative strategies and timelines

Immune checkpoint inhibitor illustration
June 12, 2026/Cancer/News & Insight

Immunotherapy Appears to Reduce the Risk of Secondary Primary Cancers

Large-scale database also reveals potential for immunotherapy to protect against cancer

T53 mutation illustration
June 10, 2026/Cancer/News & Insight

TP53 Mutation Acquisition Timing Influences Prognosis in Myeloproliferative Neoplasms

Findings may help guide discussions around prognosis and allogeneic stem cell transplantation

Woman consoling another
June 5, 2026/Cancer/Blood Cancers

Equal Access to Modern Therapy May Help Eliminate Survival Differences in Multiple Myeloma

Research underscores the importance of access to timely diagnosis and treatment in this patient population.

Multiple myeloma cells
June 4, 2026/Cancer/Blood Cancers

Machine Learning Model Outperforms Standard Risk Tools for Multiple Myeloma

A Cleveland Clinic model combining clinical staging, genomics and AI predicts survival with 18% greater accuracy — and could help match patients to more effective treatments.

Dr. Kamath & colleagues in the lab
June 2, 2026/Cancer/News & Insight

Tissue Tumor Mutation Burden Outperforms Blood-Based Testing for Predicting Immunotherapy Response

Study serves as ‘cautionary tale’ for physicians tempted to rely on liquid biopsy results alone

Patient with nebulizer
June 1, 2026/Cancer/Innovations

Adding Novel Inhaled Agent May Improve Lung Cancer Outcomes

Direct delivery of viral-based vector KB707 to the lungs may boost anti-tumor response and help overcome immune checkpoint inhibitor resistance

Ad